S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Time to Sell NVDA? (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
Time to Sell NVDA? (Ad)
Stock market today: Wall Street quiet after breaking more records; another bank reports trouble
China's manufacturing activity contracts for 5th straight month despite policy support
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Time to Sell NVDA? (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
Time to Sell NVDA? (Ad)
Stock market today: Wall Street quiet after breaking more records; another bank reports trouble
China's manufacturing activity contracts for 5th straight month despite policy support
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Time to Sell NVDA? (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
Time to Sell NVDA? (Ad)
Stock market today: Wall Street quiet after breaking more records; another bank reports trouble
China's manufacturing activity contracts for 5th straight month despite policy support
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Elon Musk's "Project Dojo" is a Game-Changer (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Time to Sell NVDA? (Ad)
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
Time to Sell NVDA? (Ad)
Stock market today: Wall Street quiet after breaking more records; another bank reports trouble
China's manufacturing activity contracts for 5th straight month despite policy support
NASDAQ:XNCR

Xencor (XNCR) Stock Price, News & Analysis

$22.95
+0.16 (+0.70%)
(As of 02/29/2024 ET)
Today's Range
$22.85
$23.92
50-Day Range
$18.65
$26.52
52-Week Range
$16.49
$32.59
Volume
1.14 million shs
Average Volume
756,588 shs
Market Capitalization
$1.40 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.71

Xencor MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
55.6% Upside
$35.71 Price Target
Short Interest
Bearish
10.53% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.24
Upright™ Environmental Score
News Sentiment
-0.07mentions of Xencor in the last 14 days
Based on 33 Articles This Week
Insider Trading
Selling Shares
$1.99 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.70) to ($3.97) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.64 out of 5 stars

Medical Sector

279th out of 957 stocks

Pharmaceutical Preparations Industry

128th out of 433 stocks


XNCR stock logo

About Xencor Stock (NASDAQ:XNCR)

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ib clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; Novartis XmAb, which is in Phase I clinical trial; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.

XNCR Stock Price History

XNCR Stock News Headlines

Xencor (NASDAQ:XNCR) Rating Reiterated by Piper Sandler
Revolutionary Device Redefines Cancer Detection
Discover the breakthrough device that could transform the lives of the estimated 68 million Americans affected by skin cancer. Achieving unprecedented accuracy, this device identifies cancer's molecular signature in just 1.5 seconds. This innovation marks a rapid advance in the battle against cancer. See how investors are unlocking 10% in bonus shares for a limited time.
Xencor (NASDAQ:XNCR) Downgraded by StockNews.com
Xencor Inc XNCR
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
Xencor Full Year 2023 Earnings: Misses Expectations
Xencor (NASDAQ:XNCR) Shares Gap Down on Disappointing Earnings
Xencor Q4 2023 Earnings Preview
Xencor to Present at Upcoming Investor Conferences
Unveiling 4 Analyst Insights On Xencor
Xencor (XNCR) Gets a Buy from TD Cowen
Xencor: Q4 Earnings Snapshot
Xencor earnings preview: what Wall Street is expecting
6XNCR : Earnings Preview: Xencor
Xencor (XNCR) to Release Earnings on Tuesday
Xencor (NASDAQ:XNCR) Stock Rating Upgraded by StockNews.com
KPTI Aug 2024 1.000 call
See More Headlines
Receive XNCR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xencor and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
2/29/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:XNCR
Employees
281
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.71
High Stock Price Target
$50.00
Low Stock Price Target
$24.00
Potential Upside/Downside
+55.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-55,180,000.00
Pretax Margin
-82.23%

Debt

Sales & Book Value

Annual Sales
$168.34 million
Book Value
$12.14 per share

Miscellaneous

Free Float
57,850,000
Market Cap
$1.40 billion
Optionable
Optionable
Beta
0.70
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Bassil I. Dahiyat Ph.D. (Age 54)
    Co-Founder, CEO, President & Director
    Comp: $1.08M
  • Mr. John J. Kuch (Age 65)
    Senior VP & CFO
    Comp: $660.75k
  • Dr. John R. Desjarlais Ph.D. (Age 60)
    Executive VP of Research & Chief Scientific Officer
    Comp: $711.45k
  • Ms. Celia E. Eckert J.D. (Age 51)
    Senior VP, General Counsel & Corporate Secretary
    Comp: $646.25k
  • Dr. Nancy Valente M.D. (Age 65)
    Executive VP & Chief Development Officer
    Comp: $28.16k
  • Mr. Charles Liles
    Associate Director and Head of Corporate Communications & Investor Relations
  • Ms. Jennifer Sandoz
    Vice President of Human Resources
  • Dr. Jeremy Grunstein Ph.D.
    Senior Vice President of Business Development
  • Mr. Kirk Rosemark RAC (Age 59)
    Senior Vice President of Regulatory Affairs & Quality Assurance
  • Mr. Eric P. Kowack
    Senior Vice President of Program Leadership & Alliance Management














XNCR Stock Analysis - Frequently Asked Questions

Should I buy or sell Xencor stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xencor in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" XNCR shares.
View XNCR analyst ratings
or view top-rated stocks.

What is Xencor's stock price target for 2024?

8 analysts have issued 1 year price targets for Xencor's stock. Their XNCR share price targets range from $24.00 to $50.00. On average, they predict the company's share price to reach $35.71 in the next year. This suggests a possible upside of 55.6% from the stock's current price.
View analysts price targets for XNCR
or view top-rated stocks among Wall Street analysts.

How have XNCR shares performed in 2024?

Xencor's stock was trading at $21.23 at the start of the year. Since then, XNCR shares have increased by 8.1% and is now trading at $22.95.
View the best growth stocks for 2024 here
.

When is Xencor's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our XNCR earnings forecast
.

How were Xencor's earnings last quarter?

Xencor, Inc. (NASDAQ:XNCR) issued its earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of $0.36 by $0.67. The biopharmaceutical company earned $44.70 million during the quarter, compared to the consensus estimate of $77.63 million. Xencor had a negative net margin of 74.90% and a negative trailing twelve-month return on equity of 18.67%. The business's quarterly revenue was up 106.9% on a year-over-year basis. During the same period in the previous year, the business posted ($0.20) EPS.

What ETFs hold Xencor's stock?
What is Bassil I. Dahiyat's approval rating as Xencor's CEO?

6 employees have rated Xencor Chief Executive Officer Bassil I. Dahiyat on Glassdoor.com. Bassil I. Dahiyat has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Xencor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xencor investors own include Intelsat (I), Bank of America (BAC), Apollo Global Management (APO), Cypress Semiconductor (CY), NVIDIA (NVDA), AbbVie (ABBV), Exelixis (EXEL), Intel (INTC), AMC Entertainment (AMC) and Ciena (CIEN).

Who are Xencor's major shareholders?

Xencor's stock is owned by many different institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (14.62%), Vanguard Group Inc. (11.12%), Price T Rowe Associates Inc. MD (5.72%), Price T Rowe Associates Inc. MD (5.72%), Armistice Capital LLC (2.46%) and Dimensional Fund Advisors LP (2.10%). Insiders that own company stock include Allen Yang, Bassil I Dahiyat, Bassil I Dahiyat, Celia Eckert, John J Kuch and John R Desjarlais.
View institutional ownership trends
.

How do I buy shares of Xencor?

Shares of XNCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:XNCR) was last updated on 3/1/2024 by MarketBeat.com Staff